lpsos

JUNE 2020

© lpsos 2020



Introduction

PREPARING FOR THE FUTURE OF THE OPERATING ROOM: ROBOTICS

Introduction

Brief History

Drivers & Barriers

The Future



Imagine a future where surgical robots have become small and affordable enough to be found even in non-specialized hospitals and outpatient clinics outside of a major metropolis...

Imagine a time when these robots can be put onto "auto-drive" mode to complete

Impact of COVID-19

Imagine a world where a specialist can conduct operations in several cities in multiple countries – all in a day's work from one centralized location...

certain parts of an operation faster and more accurately than humans...

About Ipsos MD&D





Introduction

Brief History

Introduction

Drivers & Barriers


The Future

Impact of COVID-19

Summary

About Ipsos MD&D

Operating rooms (ORs) are one of the most critical areas and highest cost centers of a hospital – in some cases making up over 40% of total expenses. This makes them a prime target for innovation to improve efficiency and precision. The past decade has seen a significant shift in the use of sophisticated and automated technology in the OR, including:





https://www.mddionline.com/future-digital-surgery

https://www.merraine.com/5-disruptive-technologies-that-are-revolutionizing-the-operating-room https://new.siemens.com/global/en/products/buildings/markets/smart-hospitals/operating-room.html

We spoke to 10 leading robotic surgeons around the globe and collected quantitative data, together with SERMO, from 243 surgeons across the US and Europe to assess their take on what has worked well, where improvements are needed and what the future will hold for robotic surgery. This paper focuses on the impact that robotics has had on OR design, surgical practice and outcomes and highlights from our expert interviews.



Introduction

Brief history

Drivers & Barriers

The Future

Impact of COVID-19

Summary

About Ipsos MD&D

Brief history

The idea of robotic surgery was initially developed for the military, in order to enable surgeons to operate on wounded soldiers from a remote and safe location. They first entered the civilian operating room two decades ago.

One might think that robotics would have had an immediate and transformative effect on surgical practice and outcomes, when first introduced in 1999 for urology, gynecology and bariatric surgeries. However, much like electricity, the computer and the worldwide web, the "Productivity Paradox" holds true – it takes on average 20 years for an innovation to reap productivity benefits. The thing about revolutionary technology is that it changes everything, and changing everything takes imagination. Instead of just replacing minimally invasive or open-surgical techniques with robots, surgeons and hospitals have had to redesign their ORs and ways of doing things to

get the best out of robotics. As technology advances and efficiencies are recently being realized, we see a broadening of robotic design and expanded use for other indications.

Two decades after its initial launch, patents for Intuitive's Da Vinci systems are expiring, opening up the market to new competitor products thus changing the market dynamics. Companies such as Stryker, Smith & Nephew, Zimmer Biomet and Globus Medical have all made acquisitions (and/or signed collaborations) to acquire or enhance robotic surgical platforms.

2015	2016	2017	2018	2019
		_		
Sciences. Verb plans to launch Orthotaxy in 2018 for its orthop Johnson & Johnson spent US\$	joint venture, Verb Surgical, with Verily Life its digital MIS platform in 2020. After acquiring bedic-surgery digital prototype in 2018, 3.4 billion in February 2019 to acquire Auris uscopy platform to the portfolio.	biggest buy since Covidien) software to launch an u June 2019, Medtronic h	azor Robotics for US\$1.7 billion (its quickly integrating its own Stealth upgraded version of the platform in nas also announced its partnership o integrate their 3D vision systems	Siemens Healthineers paid US\$1.1 billion for Corindus Vascular Robotics' minimally invasive surgery (MIS) platform for coronary, peripheral and neurovascular operations.





Introduction

Brief History

The Future

Drivers & barriers

PREPARING FOR THE FUTURE OF THE OPERATING ROOM: ROBOTICS

Drivers & barriers

There are six main drivers to the growing use of robotic surgical platforms:

- 1. The aging population, global burden of disease and subsequent general hospital bed shortages are highly motivating reasons to use robotics as in many cases, patient recovery time is reduced
- Introduction of less expensive systems and the launch of systems that do not require use of disposable instruments is bringing down the per procedure cost, meaning more can afford robotics
- **3. Technological advances** in robotic systems are enabling more widespread use, e.g. haptic feedback and modular components increasing versatility, as well as the availability of portable devices that allow transfer between operating rooms and create suitability in ambulatory surgery centers
- **4. Increased emphasis on physician and operating room safety** drives use of robotics as they have the potential to significantly reduce and potentially eliminate the need for intraoperative fluoroscopy
- 5. Integration of robotic training into medical residency programs will further drive the adoption of robotics within each surgical specialty
- 6. Regulatory approvals of robotic systems for additional clinical indications and in new geographic markets has led to procedure volume growth

Impact of COVID-19

Summary

About Ipsos MD&D



While use of robotic surgical platforms have been increasing, there are geographical differences to adoption.

- The volume of demand is the highest in the US, at around 70% of global sales, due to procedure volume growth, the reimbursement system (robot-assisted is classified as minimally invasive, which is covered by insurers), and the trend amongst manufacturers to invest a larger portion of their efforts in the US.
- Reduced spending and smaller budgets for healthcare providers have limited the overall volume of installed robotic platforms in Europe, with 14% of global sales in the five major EU markets.
- Asian countries, particularly Japan, China and South Korea with substantial investment in technological advancements, serve as new revenue pockets for the medical
 robotic systems market. High investment costs still limit the installation of robotics to large tertiary/university hospitals in key metropolitan cities, where there is the
 highest suitable case load.



Brief History

The Future

Drivers & barriers

Impact of COVID-19

About Ipsos MD&D

PREPARING FOR THE FUTURE OF THE OPERATING ROOM: ROBOTICS

Drivers & barriers

It is generally accepted that robotic surgical systems offer similar benefits to those offered by minimally invasive surgery (MIS), including shorter recovery time, less scarring and reduced healthcare costs, due to shorter hospital stays driving uptake over open methods. The jury is still out on whether the additional cost of robotics over traditional laparoscopic procedures carries sufficient additional benefits.

Key Benefits, and how they are measured by hospitals to justify investment, fall into three categories:

General benefits

- Experts found it easier to train on robotics than anticipated
- Robotics is an "easier" option
- Ability to treat higher patient case loads

Benefits during surgery

- Seen as an enabling technology
- Improved precision and ergonomics
- Allows surgeons to perform otherwise difficult or impossible surgeries
- Enables more efficient use of the OR

Benefits post-surgery

- Post-surgical complications are less frequent
 and complex
- Reduced recovery time
- Fewer readmissions at day 7, 30, 90
- Reduced post-operative pain and scarring

Even with the benefits presented and being on the market for two decades (and counting), robotic surgical systems are still not considered mainstream. A number of factors have, and some will continue to, impede the adoption to these systems.

Key Barriers

- Insufficient clinical evidence
- Lack of competition means high costs
- Lack of (adequate) government reimbursement
- Access to/availability of robotic platforms or trained surgeons
- Patient acceptance and demand

https://www.medicaldevice-network.com/features/da-vinci-surgical-robot-competitors/Ou et al., 2011



Introduction

Brief History

Drivers & Barriers

The Future

Impact of COVID-19

Summary

About Ipsos MD&D



While ORs have been transforming over the past decade, there are even more innovative tools being developed to further enhance efficiency and precision. Some of these tools will have an impact in the short term but more "idealistic" innovations (such as advanced AI, remote-controlled surgery) will take longer to reach the OR. The experts we spoke to anticipate it will take at least another decade to get to a point where these innovations are truly integrated into the OR.

Al is already breathing new life into robotic-assisted surgeries making it easier for surgeons to navigate small incisions and limit strains on joints. In the future, advanced Al will allow robots to "explore" the patient's body and give the surgeon several courses of action to choose from. Once an action is selected, the robot could execute the fine precision work, while the surgeon supervises.

Another aspect of futuristic robotic-assisted surgeries will enable one surgeon to oversee procedures in multiple hospitals and countries, without having to leave his or her position, thus granting access to specialized care in smaller, non-specialized hospitals – as long as the hospitals can have the robotic platform. This model will establish a more decentralized network-based care, with surgeons overseeing procedures from their centers of excellence, while procedures are taking place out in the larger community.

While use of robotic surgical platforms have been increasing, there are geographical differences to adoption.

- 1. Increased competition, price reduction and improved access
- 2. Increasing indications for robotics

The future

- 3. Continued improvements in digital imaging
- 4. Miniaturization and migration out of the OR
- 5. Increased use of data/smart systems
- 6. Peripheral technology is expected to become more widespread
- 7. New/updated innovations focused on ease of use, better precision and ergonomics (e.g., single port systems)



Impact of COVID-19

Brief History

COVID-19 has had a profound impact globally. The biggest impact on surgeons is a drastic reduction in caseload, as elective surgeries are being postponed or canceled. As hospitals begin to open up for elective surgeries, various changes are likely to occur to accommodate the new environment.

Drivers & Barriers

The Future

Impact of COVID-19

Summary

About Ipsos MD&D

 $\langle n \rangle$

Prioritization on a backlog of elective surgeries, as only urgent/emergency cases have been conducted and

have been conducted and elective procedures have been postponed. Impact on procedural volume differ by country and even regionally within a country. As a result, rollouts will differ as well. Individual hospitals are already planning how to address the backlog, while balancing out resources consumed by treating COVID-19 and addressing patient concerns of potentially contracting an infection.

Introduction of new protocols

- Patient selection criteria are becoming more stringent, with each case being presented to a surgical committee for approval
- Patient preparation & screening to include COVID-19 tests in some cases
- Infection control during the surgery is stepped up with air seal devices, negative pressure ORs & more complex bio-cleaning

Delayed or decreased

funding for new robotic surgical platforms, as a result of COVID-19-related costs on the system. Hospitals need to recoup their losses before they consider large capital expenditures. For manufacturers, reaching out at the right time to begin discussions will be crucial. Increase in robotic use as some surgeons report that robotic surgery has less contact, so is viewed as safer. We have seen examples of various robots being used in hospitals during the COVID-19 pandemic and believe that these experiences could pave the way for more robotic use, including for surgeries.



8



Introduction

Brief History

Drivers & Barriers

The Future

Impact of COVID-19

Summary

About Ipsos MD&D

 \bigcirc

As the world grapple with the aftereffects of COVID-19, hospitals will likely take a longer time to regain their balance. Implementing new protocols, overcoming heavy financial losses and assuring the public that having surgical procedures is safe are among their immediate focus. Once things return to some form of normalcy, hospitals will then revisit purchasing needs of large capital equipment. In the meantime, manufacturers need to revisit their strategies to accommodate for the changing environment.

Summary

As the market becomes increasingly crowded, manufacturers will need to invest in the right strategy to differentiate their solutions. Leveraging a connected digital ecosystem, gathering and using data to drive better outcomes and establishing outcomes-driven payment models will pave the way of the future.

Winning strategies will use deep learning algorithms to complement surgical expertise, by enhancing real-time decision making during complex surgeries. Ultimately, while surgical robotic platforms represent a key new technology – their interoperability with connected operating rooms of the future will be equally important for their long-term prospects.



Join our webinar for more insights and data

To glean more details on the topics covered in this paper, including the many opportunities for manufacturers to leverage, please register for our July 15 webinar with live events hosted across different time zones:



Im	12			пп	1			6
				UU				

Brief History

Drivers & Barriers

The Future

Impact of COVID-19

About Ipsos



About Ipsos' Medical Devices & Diagnostics Center of Expertise

Expertise across the product lifecycle

Operating in more than 50 countries, our 1000+ healthcare experts support key business decisions for our clients throughout the commercial lifecycle – from early-stage strategy, through to product launch and performance optimisation. We do this through a uniquely integrated combination of therapeutic, market, analytical and commercial expertise, as well as gold standard, proprietary real-world evidence.



Early development Market mapping/landscaping

- Assessment of unmet needs
- Regulatory environment
- Competitor landscape
- Current practice
- Patient pathways

Opportunity assessment & Identification

- Market sizing & forecasting
- Market segmentation



Late development New product design &

- development
 - Innovation workshops with R&D, marketing & customers to generate new ideas
 - Fine-tuning existing concepts

Concept testing

- Pricing & value assessment
- Human factors/usability testina
- Conioint analysis of best features/value per feature



Launch

Launch strategy

- Message/positioning testing Price optimisation
- Value proposition/story refinement
- Engagement strategies
- Preferred marketing channels
- Target identification
- Customer lovalty

satisfaction

Value optimisation strategies

Post-launch

• Advertising and messaging

Sales force effectiveness

Awareness & usage

Customer experience/

Brand health tracking

effectiveness

Brand equity



Portfolio management Next-gen/upgrade strategies

- Assessment of unmet needs
- Identification of gaps in a portfolio

Portfolio (merger) management

- Optimisation of existing portfolio
- Bisk of cannibalisation of new product design or merging of two company portfolios
- Rebranding effect in case of company mergers